Ondek Limited Announced the Appointment of Dr Jenny Harry as CEO

Ondek Limited Announced the Appointment of Dr Jenny Harry as CEO

March 18, 2013 -- Australian drug delivery system company Ondek Limited today announced the appointment of Dr Jenny Harry as Chief Executive Officer.

Ondek is developing innovative ways to deliver medical therapies using the groundbreaking discoveries of Australian Nobel Laureate Barry Marshall. The Company is currently working to use the stomach bacteria that helped win Dr Marshall the top prize in medicine to fight childhood asthma and allergies.

Ondek Chairman Peter Hammond said, "Dr Harry will play a key role in the global commercialisation of Ondek's novel drug delivery technology. She has already had a significant and positive impact on the business and her experience and skills will be invaluable as we progress through the clinic and negotiate commercial alliances."

Dr Harry is an experienced CEO of global biotechnology businesses. Before joining Ondek she served as CEO and Managing Director of Tyrian Diagnostics Limited (ASX: TDX) where she led the transformation of the Company from research and development to diagnostics and oversaw commercialisation of its first diagnostic products. She has experience in leading high performing teams, strategic planning and portfolio development, structuring and negotiating agreements with multi-nationals, raising capital for early stage biotechnology companies and investor relations. Dr Harry has a PhD in developmental biology from Macquarie University, and is a graduate of the Harvard Business School General Manager Program and the Australian Institute of Company Directors. Dr Harry is based in Sydney at the offices of Exto Partners Pty Ltd.

For more information contact:

Dr Jenny Harry

CEO Ondek Limited

02 9332 0600

Tim Allerton or Andrew Geddes

City PR

02 9267 4511

About Ondek

Ondek Pty Ltd is an Australian biotechnology company developing a novel drug delivery platform, known as the "Helicobacter pylori Platform Technology" (HPPT).

The platform utilises the unique characteristics of a genetically modified Helicobacter pylori bacterium to deliver a diverse range of therapeutics to the patient, including immune therapies, biopharmaceuticals, other drugs and vaccines.

Ondek was founded by Professor Barry Marshall, a world authority and co-discoverer of the Helicobacter pylori organism and co-recipient of the 2005 Nobel Prize for Medicine and Physiology.